Galectin Therapeutics Inc (GALT : NASDAQ)
Common Stock
$3.68
USD
+0.00 (%)
Last updated: 2026-09-17
Get GALT alerts:
GALT
Galectin Therapeutics Inc
WealthAwesomePerformance
1 Day
-1.34%
1 Week
-9.14%
1 Month
+4.84%
YTD
+32.85%
Key Statistics
Market Cap
$371.13M
52W High
$7.13
52W Low
$2.03
P/E Ratio
-
50 Day MA
$3.80
200 Day MA
$3.38
Beta
0.39
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $3.73 | $3.79 | $3.69 | $3.71 | $3.71 | 171,100 |
| 9/16/2026 | $3.71 | $3.80 | $3.61 | $3.68 | $3.68 | 274,000 |
| 9/15/2026 | $3.82 | $3.83 | $3.58 | $3.73 | $3.73 | 323,100 |
| 9/14/2026 | $3.95 | $4.09 | $3.82 | $3.84 | $3.84 | 337,900 |
| 9/11/2026 | $3.92 | $4.01 | $3.84 | $3.91 | $3.91 | 243,600 |
| 9/10/2026 | $4.00 | $4.05 | $3.84 | $3.90 | $3.90 | 253,000 |
| 9/9/2026 | $4.13 | $4.34 | $4.04 | $4.05 | $4.05 | 515,600 |
| 9/8/2026 | $4.60 | $4.65 | $4.10 | $4.14 | $4.14 | 393,300 |
| 9/4/2026 | $4.33 | $4.72 | $4.33 | $4.61 | $4.61 | 473,300 |
| 9/3/2026 | $4.50 | $4.60 | $4.22 | $4.35 | $4.35 | 244,100 |
Analyst Price Targets
Based on 1 analyst covering GALT · as of Sep 17, 2026
Wall Street analysts forecast GALT stock price to rise 198.9% over the next 12 months.
Consensus
Strong Buy5.00 / 5.00
Avg. Target
US$11.00
+198.9% Upside
Current Price
US$3.68
Last close
Analyst Breakdown (1 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GALT's historical volatility
30-Day Vol
76.4%
Annualized
90-Day Vol
106.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$4.44
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$3.94 | US$3.02 – US$5.13 |
| 60 trading days | US$4.18 | US$2.88 – US$6.07 |
| 90 trading days | US$4.44 | US$2.81 – US$7.00 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -3727.95%
- EPS (Diluted)
- -0.43
- Book Value
- -2.10
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GALT.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |